Momelotinib purchasing channels and pharmacy guide in China

Momelotinib is an oral kinase inhibitor that has attracted clinical attention in recent years due to its potential in the treatment of myelofibrosis (MF). Myelofibrosis is a chronic progressive myeloproliferative disease that mainly affects the production of blood cells and is often accompanied by symptoms such as anemia, splenomegaly, fatigue, and bone marrow fibroplasia.

The indications for Momelotinib mainly include moderate-to-high-risk primary myelofibrosis (PMF) and secondary MF, including cases evolved from polycythemia vera (PV) or essential thrombocythemia (ET). One of the characteristics of this drug is that it can not only relieve the symptoms of splenomegaly, but also have certain effects on MF-related anemia. This is relatively rare among existing drugs, so it is regarded as a candidate drug with multiple therapeutic targets.

In the Chinese market, the original drug molotinib has not yet been officially launched, so it is not yet included in the category of drugs in the national medical insurance catalog. This also means that the drug is usually not available in domestic public hospitals and regular pharmacies, and patients can only obtain it through other legal channels. Currently, some overseas drug platforms or authorized pharmacies in Hong Kong and Macao can provide the US version of the original drug. Common specifications include 100mg, 150mg and 200mg packaging formats. Each box has 30 tablets, which can be used for one month of treatment. Since there is currently no official channel to introduce the drug in China, the drug is mostly obtained through overseas purchasing, self-importation, etc. The price is relatively high and the acquisition cycle is long. It is recommended that patients pay attention to legality and drug authenticity when choosing channels.

In addition, in recent years, the first generic version of molotinib has been approved for marketing in some countries. Its active ingredients are basically the same as the original drug, its efficacy is equivalent in clinical controls, and its price is more affordable. Although generic drugs have not yet entered the Chinese market, some international pharmacies have provided delivery services, becoming another option that patients are paying attention to.

Reference materials:https://en.wikipedia.org/wiki/Momelotinib